Study of Oral Topotecan With Bevacizumab for Recurrent Small Cell Lung Cancer
Status:
Completed
Trial end date:
2010-05-01
Target enrollment:
Participant gender:
Summary
Combination of Hycamtin (topotecan) and Avastin (bevacizumab) could allow killing of both
endothelial and neoplastic cells. We postulate that addition of bevacizumab to topotecan will
increase delivery of topotecan to tumor cells and may enhance activity of topotecan in
patients with previously treated small cell lung cancer and improve progression free
survival.